AVDL News and Press, Avadel Pharmaceuticals plc From 10/30/23

DUBLIN, Ireland, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, November 8, 2023, to p...

– 17 abstracts accepted, including new and encore data emphasizing clinical benefit and patient preference for a once-at-bedtime narcolepsy treatment option – – Company to host symposium on October 24 with leading KOLs discussing evolution of the narcolepsy tre...

DUBLIN, Ireland, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the Jefferies Biotech CNS/Neuro Summit ...

2023-09-29 13:05:39 ET More on AbbVie, Alnylam, etc. AbbVie: Company Vs. Stock, A Gentle Facelift Would Be Nice (Technical Analysis) AbbVie Vs. AstraZeneca: Battle Of The Pharmaceutical Behemoths AbbVie Inc. (ABBV) Morgan Stanley 21st Annual Global Healthcare Brokers...

2023-08-21 23:20:12 ET Summary Avadel's Q2 2023 earnings report shows promising growth and FDA endorsement of Lumryz for narcolepsy treatment. Lumryz has seen positive commercialization with high prescriber enrollments and reimbursement successes. Avadel presents potential gro...

2023-08-09 14:02:09 ET Avadel Pharmaceuticals plc (AVDL) Q2 2023 Earnings Conference Call August 9, 2023, 8:30 AM ET Company Participants Austin Murtagh - Stern Investor Relations Gregory Divis - Chief Executive Officer Richard Kim - Chief Commercial Officer ...

2023-08-09 07:08:37 ET Avadel Pharmaceuticals press release ( NASDAQ: AVDL ): Q2 GAAP EPS of -$0.83 misses by $0.45 . Cash, cash equivalents and marketable securities were $160.5 million as of June 30, 2023. In May 2023, the Company exercised its option to exchange $10...

-- Successfully commenced U.S. commercial launch of LUMRYZ™ -- -- Received final FDA approval for LUMRYZ with orphan drug exclusivity granted through May 1, 2030 -- -- Significant early progress on payor coverage, prescriber certifications and patient enrollments ...

2023-08-08 12:52:40 ET Avadel Pharmaceuticals ( NASDAQ: AVDL ) is scheduled to announce Q2 earnings results on Wednesday, August 9th, before market open. The consensus EPS Estimate is -$0.33 and the consensus Revenue Estimate is $0.73M. Over the last 3 months, EPS esti...

2023-08-08 10:46:10 ET Major earnings expected before the bell on Wednesday include: Brookfield Asset Management ( BAM ) 3D Systems ( DDD ) PENN Entertainment ( PENN ) Roblox ( RBLX ) Sony Group ( SONY ) For further details see: Notable ea...